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H I V / A I D S M A J O R A R T I C L E
Missed Visits and Mortality among Patients
Establishing Initial Outpatient HIV Treatment
Michael J. Mugavero,1 Hui-Yi Lin,2 James H. Willig,1 Andrew O. Westfall ,4 Kimberly B. Ulett,1 Justin S. Routman,1
Sarah Abroms,1 James L. Raper,1 Michael S. Saag,1 and Jeroan J. Allison3
Divisions of 1Infectious Diseases, 2Medical Statistics Section, and 3General Internal Medicine, Department of Medicine, and 4Department
of Biostatistics, University of Alabama at Birmingham
Background. Dramatic increases in the number of patients requiring linkage to treatment for human im-
munodeficiency virus (HIV) infection are anticipated in response to updated Centers for Disease Control and
Prevention HIV testing recommendations that advocate routine, opt-out HIV testing.
Methods. A retrospective analysis nested within a prospective HIV clinical cohort study evaluated patients who
established initial outpatient treatment for HIV infection at the University of Alabama at Birmingham 1917 HIV/
AIDS Clinic from 1 January 2000 through 31 December 2005. Survival methods were used to evaluate the impact
of missed visits during the first year of care on subsequent mortality in the context of other baseline sociode-
mographic, psychosocial, and clinical factors. Mortality was ascertained by query of the Social Security Death
Index as of 1 August 2007.
Results. Among 543 study participants initiating outpatient care for HIV infection, 60% missed a visit within
the first year. The mortality rate was 2.3 deaths per 100 person-years for patients who missed visits, compared
with 1.0 deaths per 100 person-years for those who attended all scheduled appointments during the first year after
establishing outpatient treatment ( ). In Cox proportional hazards analysis, higher hazards of death werePp .02
independently associated with missed visits (hazard ratio, 2.90; 95% confidence interval, 1.28–6.56), older age
(hazard ratio, 1.58 per 10 years of age; 95% confidence interval, 1.12–2.22), and baseline CD4+ cell count !200
cells/mm3 (hazard ratio, 2.70; 95% confidence interval, 1.00–7.30).
Conclusions. Patients who missed visits within the first year after initiating outpatient treatment for HIV
infection had more than twice the rate of long-term mortality, compared with those patients who attended all
scheduled appointments. We posit that early missed visits are not causally responsible for the higher observed
mortality but, rather, identify those patients who are more likely to exhibit health behaviors that portend increased
subsequent mortality.
In September 2006, the US Centers for Disease Control
and Prevention (CDC) released updated HIV testing
recommendations that advocated routine, opt-out HIV
testing for adults in all health care settings [1]. The
rationale for this paradigm shift from risk-based, opt-
in testing to routine, opt-out testing included the high
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proportion of HIV-infected individuals who are una-
ware of their status, the common occurrence of late
diagnosis with advanced disease progression, and the
consistently high number of incident cases of HIV in-
fection that are reported annually despite extensive pre-
vention efforts. An estimated 25% of individuals living
with HIV infection in the United States are unaware
of their HIV infection status [2]. Furthermore, late pre-
sentation is frequently observed, with more than one-
half of patients with newly diagnosed infection entering
care with initial CD4+ cell counts !200 cells/mm3 [3–
7]. The updated recommendations aim to reduce the
number of infected persons who are unaware of their
infection status and to facilitate earlier diagnosis of HIV
infection [1], which may ultimately benefit the health
of individuals, as well as the public health, through
reduced transmission and a reduction in the number
of secondary infections.
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Dramatic increases in the number of individuals in need of
HIV treatment are anticipated in response to the implemen-
tation of the updated CDC HIV testing recommendations [8,
9]. The recommendations emphasize the importance of linkage
to clinical and preventive services for patients with newly di-
agnosed infection [1]. Studies show that 20%–40% of patients
with recently diagnosed HIV infection do not attend an out-
patient clinic visit within 6 months after receipt of their di-
agnosis [10, 11]. Among those who successfully initiate out-
patient care, missed visits and loss to follow-up during the year
after attending a first HIV clinic visit are common and are
associated with delays in the receipt of antiretroviral medica-
tions [7, 12, 13]. However, to our knowledge, no published
study has evaluated the relationship between missed visits in
the first year of HIV care and long-term survival. We hypoth-
esized that patients who missed visits in the year after estab-
lishing outpatient HIV treatment would have higher subsequent
mortality in the context of other baseline sociodemographic,
psychosocial, and clinical factors that are associated with
survival.
PATIENTS AND METHODS
Cohort description. The University of Alabama at Birming-
ham (UAB) 1917 HIV/AIDS Clinic Cohort Observational Da-
tabase Project (UAB 1917 Clinic Cohort) is described in detail
elsewhere [14–16]. Here, we conduct a retrospective cohort
study nested in the UAB 1917 Clinic Cohort to evaluate the
impact of missed visits on long-term survival among patients
establishing initial outpatient HIV treatment.
Eligibility criteria. Patients who attended an initial pri-
mary HIV care visit at the UAB 1917 Clinic from 1 January
2000 through 31 December 2005 and had received no prior
outpatient HIV treatment at another facility were included in
this analysis. Medical records of patients attending a first visit
at the UAB 1917 Clinic during the study period were reviewed
independently by 2 abstractors (J.S.R. and S.A.) to determine
whether a patient had previously received HIV treatment else-
where and was therefore ineligible for study participation. Dis-
crepancies in reporting (!2% of records) were arbitrated by 2
physician HIV care providers at the UAB 1917 Clinic (M.J.M.
and J.H.W.). These criteria were employed because of our in-
terest in studying a homogeneous sample of patients who were
establishing initial outpatient HIV treatment, while excluding
patients who had previously received care at other facilities
(who represent a different sample group). We were interested
in evaluating the impact of missed visits within the first year
after establishing care (exposure) on long-term survival (out-
come); therefore, patients who died within 1 year after their
initial visit were excluded from analyses, because they did not
have appointment attendance data for the entire exposure
period.
Measures. Appointment attendance during the first year
after establishing outpatient care was the primary independent
variable of interest. Missed visit status was determined for all
study participants by evaluating appointment attendance re-
cords for 365 days after an initial attended primary HIV care
visit. Urgent care and subspecialty visits (e.g., dermatology) at
the clinic were excluded. Appointment status at the UAB 1917
Clinic is managed with a Web-based software program that is
updated daily. Consistent with previous studies [17–20], only
missed visits for which a patient did not call the clinic to cancel
or reschedule (i.e., “no show” visits) were included in the
missed visit measure. Appointments that were cancelled by the
clinic, those that a patient called to cancel in advance, or those
that were cancelled because the patient was hospitalized are not
included in the missed visit measure. Missed visit status was
recorded as a dichotomous measure, with patients characterized
as having no missed visits or 1 missed visit during the first
year of outpatient HIV treatment.
Other covariates were selected a priori and included sociod-
emographic (age, sex, race, HIV risk group, and insurance
status), psychosocial (affective mental health, substance abuse,
and alcohol abuse disorders), and clinical measures (baseline
CD4+ cell count, plasma HIV RNA level, and receipt of anti-
retroviral therapy during the first year of care). All measures
were determined by query of the UAB 1917 Clinic Cohort
Database, which includes psychosocial measures that are cap-
tured from diagnosis lists in patients’ medical records. All cause
mortality, which was the primary outcome measure, was as-
certained by an electronic query of the Social Security Death
Index performed on 1 August 2007.
Statistical analysis. Descriptive statistics were performed
for all study variables to evaluate distributions and to ensure
that assumptions of statistical tests to be used were met. Un-
adjusted analyses using x2 tests and logistic regression and
multivariable logistic regression analysis controlling for the
aforementioned covariates were used to evaluate factors asso-
ciated with missing a primary HIV care clinic visit during the
first year after establishing initial outpatient care. The discrim-
inative capacity and fit of the multivariable model were assessed
by the C-statistic and Hosmer-Lemeshow goodness-of-fit test,
respectively.
A Kaplan-Meier plot was used to evaluate long-term survival
among patients according to missed visit status during the first
year of outpatient HIV care. Unadjusted and adjusted Cox
proportional hazards models were used to evaluate factors as-
sociated with long-term survival. Because of the relatively mod-
est number of deaths relative to the number of covariates in
the primary Cox model, a sensitivity analysis was conducted
that used propensity score methods [21]. In brief, a propensity
score for “missed visit” was determined for all study partici-
pants with use of the multivariable logistic regression model
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Figure 1. Short-term (1 year) and long-term vital status of 567 HIV-infected patients establishing initial outpatient HIV care at the University of
Alabama at Birmingham (UAB) 1917 HIV/AIDS Clinic from 1 January 2000 through 31 December 2005.
to evaluate missed visit status in the year of HIV treatment.
This approach serves to combine covariates into a single pro-
pensity score and thereby reduces the number of variables and
addresses potential concerns of model over-fitting. Next, a Cox
proportional hazards model was used to evaluate the relation-
ship between missed visit status and long-term survival while
adjusting for propensity score and for antiretroviral medication
receipt during the first year of treatment. All analyses were
conducted using SAS, version 9.0 (SAS). P values !.05 were
considered to be statistically significant.
RESULTS
During the study period, 567 (49%) of 1165 patients who at-
tended a first primary HIV care visit at the UAB 1917 Clinic
had not previously received HIV care elsewhere and were es-
tablishing initial outpatient HIV treatment. Twenty-four pa-
tients (4%) died within 1 year after their initial visit, leaving
543 patients who were included in statistical analyses. The so-
ciodemographic, psychosocial, and clinical characteristics of the
study sample (543 patients) were largely similar to those of the
overall population (1165 patients) (data not shown). Among
the 543 study participants, 325 patients (60%) had a missed
visit within the first year of care (mean no. of missed
, ), whereas 218 patients (40%) attendedvisits SD 1.8 1.1
all scheduled appointments. Thirty-two (10%) of the patients
with missed visits and 10 (5%) of the patients with perfect
appointment attendance died during longitudinal follow-up
(figure 1). Among the 325 patients with missed visits within
the first year of care, a similar mean number of missed visits
(SD) were observed among the 32 patients who died
( missed visits) and the 293 patients who survived1.9 1.6
( missed visits) during follow-up.1.8 1.1
The baseline characteristics of the 543 study participants in-
clude a mean age (SD) of years; 25% of the patients37.7 9.4
were female, and 54% were black (table 1). The HIV risk group
was men who have sex with men in 52% of the patients, het-
erosexual transmission in 40%, and injection drug use in 8%.
At initial presentation for care, one-half of the study patients
lacked private health insurance (15% had public insurance, and
35% were uninsured). Affective mental health, substance abuse,
and alcohol abuse disorders were documented in 48%, 26%,
and 20% of patients, respectively. The mean (SD) baseline
HIV RNA load was log10 copies/mL; 38% of patients4.4 1.1
had a baseline CD4+ cell count !200 cells/mm3, and 67% were
prescribed antiretroviral therapy within the first year of care.
Compared with the 543 patients who were included in the
analysis, the 24 patients who died within the first year were
more likely to have baseline CD4+ cell counts !200 cells/mm3
( ), lack private health insurance ( ), and belong toP ! .01 P ! .01
an HIV risk group other than men who have sex with men
( ; data not shown).P ! .01
Factors associated with missed visits within the first year
of care. In unadjusted analyses, missed visits within the first
year of HIV care were more common among younger patients,
female patients, black patients, HIV risk groups other than men
who have sex with men, patients lacking private health insur-
ance, and patients with substance abuse disorders (table 2). In
multivariable logistic regression analysis, missed visits were as-
sociated with younger age (OR, 0.81 per 10 years of age, 95%
CI, 0.66–0.99 per 10 years of age), black race (OR, 2.74; 95%
CI, 1.77–4.23), and having public health insurance (OR, 2.09;
95% CI, 1.10- 3.96); they were inversely associated with a base-
line CD4+ cell count of 200–350 cells/mm3 (vs. 350 cells/
mm3; OR, 0.59; 95% CI, 0.37–0.92) (table 2). Propensity scores
for missed visits were determined for each study participant
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Table 1. Baseline characteristics of 543 patients who were alive 1 year after
establishing initial outpatient HIV care at the University of Alabama at Birmingham
1917 HIV/AIDS Clinic from 1 January 2000 through 31 December 2005.
Variable
Patients
(n p 543)
Age, mean years  SD (range) 37.7  9.4 (19–70)
Sex
Male 410 (75.5)
Female 133 (24.5)
Race
White 250 (46.0)
Black 293 (54.0)
HIV infection risk factor
Men who have sex with men 277/537 (51.6)
Heterosexual sex 215/537 (40.0)
Injection drug use 45/537 (8.4)
Health insurance
Private 273 (50.3)
Public 79 (14.6)
None 191 (35.2)
Affective mental health disorder
No 280 (51.6)
Yes 263 (48.4)
Substance abuse
No 401 (73.8)
Yes 142 (26.1)
Alcohol abuse
No 437 (80.5)
Yes 106 (19.5)
Baseline CD4+ cell count
!200 cells/mm3 205/537 (38.2)
200–350 cells/mm3 95/537 (17.7)
350 cells/mm3 237/537 (44.1)
Baseline viral load, log10 copies/mL 4.4  1.1
Missed visit in first yeara
No 218 (40.1)
Yes 325 (59.8)
Antiretroviral therapy initiated within the first year of treatment
No 177 (32.6)
Yes 366 (67.4)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Of 567 patients who established
initial outpatient HIV care during this period, 543 (96%) were alive 1 year after the first clinic visit.
a Only those missed visits for which patients did not notify the clinic in advance that they would
not attend their appointment were included in this measure (“no show” visits). Appointments
cancelled by a patient in advance, those scheduled while a patient was hospitalized, and those
cancelled by the clinic were not included in the missed visit measure.
using this multivariable model and were subsequently employed
in the long-term survival sensitivity analysis.
Factors associated with long-term survival. Kaplan Meier
survival analysis revealed lower survival rates for patients who
missed a visit within the year after establishing initial outpatient
HIV treatment ( ) (figure 2). Observed mortality wasPp .02
2.3 deaths per 100 patient-years of follow-up for patients who
missed a visit, compared with 1.0 deaths per 100 patient-years
of follow-up for those who attended all clinic visits during the
first year of HIV care. In univariate survival analyses, older
patients, patients with public health insurance, and patients
who missed a visit within the first year of care had higher
hazards of death (table 3). Multivariable Cox proportional haz-
ards analysis revealed higher hazards of death among older
patients (hazard ratio [HR], 1.58 per 10 years of age; 95% CI,
1.12–2.22 per 10 years of age), patients with baseline CD4+ cell
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Table 2. Factors associated with missing an outpatient HIV clinic appointment within the first year of care
among 543 patients who were alive 1 year after establishing initial outpatient HIV care at the University
of Alabama at Birmingham 1917 HIV/AIDS Clinic, 2000–2005.
Variable
Missed visit within
the first year of care
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)a
No
(n p 218)
Yes
(n p 325)
Age, mean years  SD 38.9  9.6 36.9  9.2 0.79 (0.66–0.95)b 0.81 (0.66–0.99)b
Sex
Male 180 (82.6) 230 (70.8) 1.0 1.0
Female 38 (17.4) 95 (29.2) 1.96 (1.28–2.99) 1.11 (0.62–1.98)
Race
White 134 (61.5) 116 (35.7) 1.0 1.0
Black 84 (38.5) 209 (64.3) 2.87 (2.02–4.10) 2.74 (1.77–4.23)
HIV infection risk factor
Men who have sex with men 133/217 (61.3) 144/320 (45.0) 1.0 1.0
Heterosexual sex 72/217 (33.2) 143/320 (44.7) 1.83 (1.27–2.65) 1.23 (0.73–2.06)
Injection drug use 12/217 (5.5) 33/320 (10.3) 2.54 (1.26–5.12) 1.82 (0.78–4.25)
Health insurance
Private 129 (59.2) 144 (44.3) 1.0 1.0
Public 18 (8.2) 61 (18.8) 3.04 (1.71–5.41) 2.09 (1.10–3.96)
None 71 (32.6) 120 (36.9) 1.51 (1.04–2.21) 1.23 (0.81–1.86)
Affective mental health disorder
No 105 (48.2) 175 (53.9) 1.0 1.0
Yes 113 (51.8) 150 (46.1) 0.80 (0.57–1.12) 0.91 (0.61–1.35)
Substance abuse
No 174 (79.8) 227 (69.9) 1.0 1.0
Yes 44 (20.2) 98 (30.1) 1.71 (1.14–2.56) 1.60 (0.93–2.74)
Alcohol abuse
No 174 (79.8) 263 (80.9) 1.0 1.0
Yes 44 (20.2) 62 (19.1) 0.93 (0.61–1.43) 0.82 (0.50–1.34)
Baseline viral load, log10 copies/mL 4.4  1.1 4.3  1.1 0.95 (0.81–1.11) 1.01 (0.84–1.20)
Baseline CD4+ cell count
350 cells/mm3 73/215 (34.0) 132/322 (41.0) 1.0 1.0
200–350 cells/mm3 36/215 (16.7) 59/322 (18.3) 0.68 (0.47–1.00) 0.59 (0.37–0.92)
!200 cells/mm3 106/215 (49.3) 131/322 (40.7) 0.91 (0.25–1.50) 0.76 (0.44–1.31)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Values in bold are statistically significant ( ). Only thoseP ! .05
missed visits for which patients did not notify the clinic in advance that they would not attend their appointment were included
in this measure (“no show” visits). Appointments cancelled by a patient in advance, those scheduled while a patient was
hospitalized, and those cancelled by the clinic were not included in the missed visit measure.
a Multivariable logistic regression model characteristics with a Hosmer-Lemeshow goodness-of-fit P value of .19 and a C-
statistic of 0.71
b Per 10 years of age.
counts !200 cells/mm3 (HR, 2.70; 95% CI, 1.00–7.30), and
patients who missed a visit within the first year of treatment
(HR, 2.90; 95% CI, 1.28–6.56). Similar hazards of death were
observed in patients with 1 missed visit and 2 missed visits,
relative to patients who had no missed visits during the first
year of outpatient treatment (data not shown). No other so-
ciodemographic or psychosocial factors were significantly as-
sociated with long-term mortality, and receipt of antiretroviral
therapy within the first year of care was not associated with
reduced hazards of death in subsequent years (table 3). Sen-
sitivity analysis using propensity score methods yielded findings
similar to those obtained by the primary analysis, with missed
visits during the first year of care increasing the hazards of
long-term mortality (HR, 2.52; 95% CI, 1.15–5.52) while con-
trolling for propensity for a missed visit and receipt of anti-
retroviral therapy (table 3).
DISCUSSION
Missed primary HIV care visits in the year after establishing
initial outpatient treatment were associated with subsequent
mortality, even when controlling for baseline CD4+ cell count
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Figure 2. Kaplan-Meier survival plot for patients establishing initial outpatient HIV care at the University of Alabama at Birmingham (UAB) 1917
HIV/AIDS Clinic from 1 January 2000 through 31 December 2005, categorized by missed visit status during the first year of care.
and receipt of antiretroviral therapy within the first year. Mor-
tality rates were 12 times higher for patients with missed visits,
compared with mortality rates for patients who attended all
scheduled appointments during the first year of care (2.3 vs.
1.0 deaths per 100 patient-years of follow-up; ). Al-Pp .02
though a modest absolute difference in mortality rate was ob-
served, these findings may have profound public health im-
plications. Because tens of thousands of patients with newly
diagnosed infection require linkage to HIV care in the United
States annually [22], extrapolation of our findings to the level
of the general population results in considerable mortality, par-
ticularly in light of the high proportion of patients who miss
visits shortly after establishing outpatient HIV treatment
[7, 12].
We posit that missed visits during the first year of care are
not causally responsible for reduced long-term survival but,
rather, may identify a subset of patients whose health behaviors
portend increased mortality. We speculate that worse subse-
quent retention in care and lower antiretroviral medication
adherence among those with missed visits ultimately places
them at increased risk of death. Accordingly, missed visits in
patients establishing initial outpatient treatment may serve as
a marker in identifying individuals at risk for poor future health
outcomes.
The current study advances earlier research by focusing on
patients who are establishing an initial linkage to outpatient
HIV treatment, which is a vulnerable population that has not
been well evaluated previously and is expected to increase dra-
matically in coming years [8, 9]. Studies assessing survival
among patients with HIV infection typically focus on individ-
uals who are initiating antiretroviral therapy or who are par-
ticipating in ongoing cohort studies [23–32]. Many new pa-
tients miss appointments and/or are lost to follow-up shortly
after attending an initial clinic visit, and they often fail to initiate
antiretroviral therapy as a result [7, 12, 13]. Furthermore, an-
tiretroviral medications may not be indicated in patients who
are establishing care based on baseline CD4+ cell counts and
plasma HIV RNA levels [33]. Among our sample, one-third of
patients did not receive antiretroviral therapy within the first
year of outpatient HIV treatment, which is a group that would
not have been evaluated if the current study employed inclusion
criteria that were based on initiation of antiretroviral therapy.
Therefore, the evaluation of missed visits and other factors
associated with survival among patients who initiate outpatient
HIV care complements earlier research and provides novel in-
sight into an understudied group. Our finding that 60% of
patients missed at least 1 visit within the first year of care
underscores the importance of the higher observed mortality
in this group. These results can be applied in clinical practice
to identify a priority population and to inform the development
of focused interventions designed to improve long-term sur-
vival in new patients initiating outpatient HIV treatment.
Similar to the association observed in this study between
missed visits and mortality in patients who are establishing HIV
care, a relationship was recently reported between retention in
care and survival among patients starting antiretroviral therapy
[23, 30]. In a study of HIV-infected male patients who received
treatment through the US Department of Veterans Affairs sys-
tem, Giordano et al. [23] also found a significant relationship
between retention in care and antiretroviral medication ad-
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Table 3. Factors associated with long-term survival among 543 patients who were alive 1 year after estab-
lishing initial outpatient HIV care at the University of Alabama at Birmingham 1917 HIV/AIDS Clinic, 2000–2005.
Analysis, variable
Univariate
hazard ratio (95% CI)
Multivariable
hazard ratio (95% CI)a
Primary analysis
Age (per 10 years) 1.61 (1.21–2.17) 1.58 (1.12–2.22)
Female sex 1.11 (0.56–2.20) 1.20(0.49–2.96)
Black race 1.05 (0.57–1.93) 0.73 (0.33–1.64)
HIV infection risk factor
Men who have sex with men 1.0 1.0
Heterosexual sex 1.23 (0.62–2.43) 0.91 (0.38–2.20)
Injection drug use 2.06 (0.81–5.23) 1.05 (0.33–3.31)
Health insurance
Private 1.0 1.0
Public 2.11 (1.03–4.32) 1.30 (0.54–3.14)
None 0.79 (0.37–1.68) 0.74 (0.32–1.71)
Affective mental health disorder 0.80 (0.44–1.47) 0.80 (0.39–1.62)
Substance abuse 1.80 (0.96–3.35) 2.08 (0.86–5.07)
Alcohol abuse 1.12 (0.53–2.35) 0.75 (0.31–1.84)
Baseline CD4+ cell count
350 cells/mm3 1.0 1.0
200–350 cells/mm3 1.32 (0.48–3.65) 1.49 (0.47–4.67)
!200 cells/mm3 2.00 (0.95–4.20) 2.70 (1.00–7.30)
Baseline viral load (log10) 1.11 (0.84–1.48) 1.02 (0.75–1.39)
Missed visit in first year 2.34 (1.15–4.77) 2.90 (1.28–6.56)
Antiretroviral therapy initiated within first year of treatment 1.00 (0.51–1.93) 0.64 (0.25–1.62)
Propensity score sensitivity analysis
Missed visit within the first year of treatment 2.34 (1.15–4.77) 2.52 (1.15–5.52)
Antiretroviral therapy initiated within the first year of treatment 1.00 (0.51–1.93) 1.18 (0.58–2.41)
Propensity score for missed visit (per 10%) 1.05 (0.87–1.26) 0.98 (0.80–1.19)
NOTE. Data in bold are statistically significant ( ).P ! .05
a In the primary analysis, the Cox proportional hazards model (i.e., multivariable hazard ratio) includes the variables listed in the
table (age, sex, race, HIV infection risk factor, health insurance, affective mental health disorder, substance abuse, alcohol abuse,
baseline CD4+ cell count, baseline viral load, missed visit status during the first year of treatment, and antiretroviral therapy receipt
within the first year of treatment). In the sensitivity analysis, the Cox proportional hazards model includes missed visit status during
the first year of treatment, propensity score for missed visit during the first year of treatment (derived from the multivariable logistic
regression model in table 2, which included age, sex, race, HIV infection risk factor, health insurance, affective mental health disorder,
substance abuse, alcohol abuse, baseline CD4+ cell count, and baseline viral load), and antiretroviral therapy receipt within the first
year of treatment.
herence, supporting our hypothesis that missed visits may iden-
tify patients who are at risk for worse outcomes during sub-
sequent care.
In addition to those individuals with missed outpatient ap-
pointments, older patients and those with more-advanced HIV
infection when establishing outpatient treatment had higher
mortality rates in our study. These findings are important, be-
cause older patients account for an increasing proportion of
patients with newly diagnosed infection who are establishing
HIV care [22]. In addition, recent studies have found that150%
of patients with newly diagnosed HIV infection who present
for initial care have baseline CD4+ cell counts that are !200
cells/mm3 [3–6], which is a characteristic that was associated
with higher rates of observed mortality in our study. Part of
the rationale behind the updated CDC HIV testing recom-
mendations is the desire to facilitate earlier diagnosis of HIV
infection and linkage to HIV care before progression to ad-
vanced disease [1]. Our study suggests that there may be long-
term benefits to patient survival if these recommendations are
successfully implemented and result in improved timeliness of
HIV infection diagnosis. Accordingly, our findings provide em-
pirical evidence to support the CDC HIV testing recommen-
dations and may serve as a call to action for health care
providers.
Of note, receipt of antiretroviral therapy during the first year
of care was not associated with subsequent mortality. After
antiretroviral treatment initiation, continuous receipt of med-
ication is necessary to achieve optimal clinical outcomes. Im-
portantly, initial receipt of antiretroviral medication does not
necessarily translate to subsequent long-term treatment; pa-
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tients are often lost to follow-up after establishing HIV care
[7, 12, 13]. It is possible that patients with missed visits within
the first year of HIV care had worse subsequent retention and
resultant poor longitudinal receipt of and adherence to anti-
retroviral medications, which contributed to the higher ob-
served long-term mortality in this group.
Our study also contributes additional knowledge regarding
engagement in care among HIV-infected individuals, which is
an area of growing interest [34]. In this study, there were strong
associations between missed visits and younger age, black race,
and public health insurance. Previously, we found that these
sociodemographic groups were less likely to attend an initial
clinic visit and establish care at our treatment center after calling
to schedule an appointment [15]. Similarly, others have re-
ported that missed visits were more common in these groups,
which bear a growing and disproportionate burden of the US
HIV infection epidemic [17, 18, 22, 35].
Formative research is needed to better understand the bar-
riers and facilitators of clinic attendance and use of services,
such that informed interventions may be developed to improve
the initial linkage and subsequent retention of infected indi-
viduals in outpatient HIV care. Case management and patient
navigation models hold promise and may link patients with
community resources and provide social support, as well as
foster problem-solving skills and build self-efficacy through
strength-based approaches that enable patients to remain better
engaged in care [11, 36]. The impact of these interventions on
long-term survival remains to be seen. Successful interventions
may have important implications not only for individual pa-
tients but also for public health and secondary HIV infection
prevention efforts. Patients who are engaged in treatment may
benefit from prevention messages and reduce their risk trans-
mission behaviors [37]. In addition, the reduction of plasma
HIV RNA levels in response to antiretroviral therapy may re-
duce sexual transmission among patients engaging in risk be-
haviors [38, 39]. Receipt of prevention messages and antiret-
roviral therapy is contingent on linkage to and retention in
outpatient HIV treatment services after diagnosis, which high-
lights the vital role played by engagement in care [34].
The findings of our study should be interpreted with respect
to the limitations of the current analyses. As with all obser-
vational studies, we are able to identify associations but cannot
attribute causality, and there is the potential for unmeasured
confounding. Our study was conducted at a single center in
the southeastern United States, and therefore, our findings may
not be generalizable to other regions of the country or to dif-
ferent patient populations. However, our patient population is
largely reflective of the sociodemographic composition of the
national HIV epidemic [22]. Mental health, substance abuse,
and alcohol abuse disorders were recorded from diagnosis lists
in the medical record and were not determined using validated
instruments. These comorbid conditions may be underrecog-
nized in clinical practice. Mortality was ascertained by query
of the Social Security Death Index, which may experience re-
porting delays from time of death to entry in the database.
However, we have no reason to believe that delayed reporting
should differentially impact individuals on the basis of ap-
pointment attendance within the first year of care. Accordingly,
we do not feel that this introduced a systematic bias that im-
pacted our findings or their interpretation.
In conclusion, patients with missed visits in the year after
establishing initial outpatient HIV care had more than twice
the rate of subsequent mortality, compared with patients who
did not miss visits, even when controlling for baseline CD4+
cell count and antiretroviral receipt within the first year. These
findings are particularly relevant in light of revised CDC HIV
testing recommendations and the anticipated large increase in
patients with newly diagnosed infection who will require linkage
to HIV care in the coming years [1, 8, 9]. Future research is
needed to identify barriers and facilitators to initial connection
and early retention in HIV care, such that informed interven-
tions can be developed to ensure that individuals derive max-
imal benefits from the tremendous recent advances in the treat-
ment of HIV infection.
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